Lv41
620 积分 2021-07-27 加入
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth
1小时前
已完结
Impacts of ageing on the efficacy of CAR-T cell therapy
1个月前
已完结
T cell exhaustion and senescence for ovarian cancer immunotherapy
2个月前
已完结
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
2个月前
已完结
CAR-T therapy in solid tumors
4个月前
已完结
Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate
6个月前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
6个月前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
6个月前
已完结
Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia
6个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
6个月前
已完结
皖公网安备34019202002308
